Management Team


Keith Ignotz, MBA
President & CEO
Co-founded Freedom Meditech as President & COO, Onset President & CEO of DiaKine Therapeutics, Co-founded SpectRx as President & COO took public. Senior VP Allergan Humphrey $100M division of Allergan.
Dr. Mark Byrne
Co-founder & Chief Technical Officer
Distinguished Professor of Chemical and Biochemical Engineering & Founding Head of the Biomedical Engineering Department at Rowen University
Dr. Paul Karpecki
Lead Optometric Advisor
Lead optometric advisor and member of its Scientific Advisory Board. His role with the company is in the development of its activities, communications, meetings and strategies relating to research and product development.
Paul Byrne
Co-founder of OcuMedic
CBO 20+yrs McKinsey, PNC Bank Execu7ve, experience on corporate strategy, ops, distribu1on, sales. Mr. Byrne is the Co-founder of OcuMedic •  MBA, Harvard
Clifford Price
Director of Communication
San Diego, CA - 28 years of experience of branding, marketing and positioning.


ADVISORY BOARDS & CONSULTANTS



Dr. Fredrick Cahn, Chief Regulatory Officer. Ph.D. from the Massachusetts Institutive of Technology in Biophysics and a BS undergraduate degree in biology from the University of California, Berkeley. Awarded the Damon Runyon Foundation Postdoctoral Fellowship. The principal investigator on 10 SBIR grants and author on numerous peer reviewed publications.

SCIENTIFIC ADVISISORY BOARD

Lynn Winterton, Ph.D. –– Scientific Advisory Board Member. (BVG Solutions-Consulting) Prior Global Head of R&D CIBA Vision with over 30 years’ experience developing and commercializing multiple, innovative contact lenses on the market today in numerous countries. Dr. Winterton was also Global Director of Strategic Partnerships at CIBA Vision and has key regulatory and manufacturing experience in the contact lens space. Upon completion of OcuMedic’s first financing, Dr. Winterton will be issued 3% equity in common stock.

Ron Dadino –– Consultant, Regulatory Affairs. (Dadino Consulting) Prior J&J VP of Product & Process Scientific Solutions leading regulatory strategy for all combination products across J&J. He has more than 33 years in pharma and medical device sector. The former J&J (Cordis) VP of Combination Product Development led global approval for first drug eluting stent combination device resulting in $1B in sales. Consulting agreement is underway and should be executed within 30 days of the date of this report. The current terms of the proposed consulting agreement are as follows: 12 month term with successive renewal unless terminated by either party; compensation $300-$150 per hour with payment upon qualified financing.

CLINICAL ADVISISORY BOARD

Steve Hamilton, MD –– Clinical Advisor, Board Certified Ophthalmologist, specializing in corneal disease and surgery, currently in private practice with over 18 years of experience.

Meredith Voyles DVM –– Pre-Clinical Advisor, Board Certified Veterinary Ophthalmologist, Previously Professor of Ophthalmology at Auburn University, currently in private practice with over 15 years of experience, with specialty training treating corneal disease as well as preclinical studies.